Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Helix Biopharma Corp. (HBPCF : OTC)

• Company Description    Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. Its primary drug candidate is L-DOS47, which is intended for the treatment of inoperable, locally advanced, recurrent, or metastatic non-small cell lung cancer. The Company's product development initiatives are focused primarily on technologies that modulate the tumor microenvironment. It's technology platform, DOS47 yielded approximately two drug product candidates, L-DOS47 and vDOS47. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. L-DOS47 is under clinical study for the treatment of non-small cell lung cancer (NSCLC). L-DOS47 has completed preclinical testing and manufacturing development, following which, regulatory approvals are obtained in Poland and the United States to conduct Phase I/II and Phase I clinical studies. V-DOS47 is an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2). Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.60 Daily Weekly Monthly 20 Day Moving Average: 0 shares Shares Outstanding: 53.02 (millions) Market Capitalization: $31.81 (millions) Beta: -0.13 52 Week High: $0.92 52 Week Low: $0.45 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.00% -3.74% 12 Week 31.90% 10.94% Year To Date 31.90% 23.52%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL North Tower 40 Temperance Street Suite 2700 - Toronto,ON M5H 0B4 CAN ph: 905-841-2300 fax: 905-841-2244 ir@helixbiopharma.com http://www.helixbiopharma.com

• General Corporate Information    Officers Jacek Antas - Chief Executive Officer and Chairman Praveen Varshney - Chief Financial Officer Jerzy Leszczynski - Director Janusz Grabski - Director Malgorzata Laube - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 422910208 SIC: 2834 Fiscal Year Fiscal Year End: July Last Reported Quarter: 04/01/25 Next Expected EPS Date: 10/23/25 Share - Related Items Shares Outstanding: 53.02 Most Recent Split Date: 8.00 (0.20:1) Beta: -0.13 Market Capitalization: $31.81 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 10/23/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 04/30/25 - - 01/31/25 - - 10/31/24 - - ROA 04/30/25 - -747.46 01/31/25 - -748.98 10/31/24 - -1,097.76 Current Ratio 04/30/25 - 0.42 01/31/25 - 0.99 10/31/24 - 0.23 Quick Ratio 04/30/25 - 0.42 01/31/25 - 0.99 10/31/24 - 0.23 Operating Margin 04/30/25 - - 01/31/25 - - 10/31/24 - - Net Margin 04/30/25 - - 01/31/25 - - 10/31/24 - - Pre-Tax Margin 04/30/25 - - 01/31/25 - - 10/31/24 - - Book Value 04/30/25 - -0.02 01/31/25 - 0.00 10/31/24 - -0.02 Inventory Turnover 04/30/25 - - 01/31/25 - - 10/31/24 - - Debt-to-Equity 04/30/25 - - 01/31/25 - - 10/31/24 - - Debt-to-Capital 04/30/25 - - 01/31/25 - - 10/31/24 - -

Powered by Zacks Investment Research ©